Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

CytoDyn Completes Safety Testing Of Cytolin(R): Benchmark For Improved Treatment Of HIV/AIDS
CytoDyn, Inc. (Pink Sheets:CYDY) has completed safety testing of its current inventory of Cytolin®, the Company"s immune-system modulator for managing HIV disease and the public health crisis afflicting communities where the infection is spreading due to unprotected sex and the other risk factors for AIDS. Tests for specific adventitious agents and other quality parameters following purification were performed by the manufacturing facility, Vista Biologicals Corporation of Carlsbad, California. The other safety tests, including in vivo general safety using two animal species, were performed by WuXi AppTec, a fully integrated pharmaceutical, biotechnology and medical-device company with facilities in St. Paul, Minnesota. WuXi AppTec provides R&D services to the biotechnology industry. Since the product is intended for use in a clinical trial, the tests conducted were those required for each new batch of a biologic agent manufactured for use in human research. The Company believes that the test results satisfy the current safety standards for the manufacturing of drugs belonging to the class of biologics. The results are summarized in the table below.
generic viagra online
Environmental Factors Instruct Lineage Choice Of Blood Progenitor Cells
The research team led by Dr. Timm Schroeder, stem cell researcher at Helmholtz Zentrum MÃønchen, has developed a new bioimaging method for observing the differentiation of hematopoietic progenitor cells (HPC) at the single-cell level. With this method the researchers were able to prove for the first time that not only cell-intrinsic mechanisms, but also external environmental factors such as growth factors can control HPC lineage choice directly. The findings, published in the current issue of the prestigious journal Science, provide an essential building block for understanding the molecular mechanisms of hematopoiesis and are an important prerequisite for optimizing therapeutic stem cell applications.
News of the day
PM&R Accepted For Abstracting And Indexing In MEDLINE
Elsevier, a world-leading publisher of scientific, technical and medical information products and services, is pleased to announce that PM&R - The journal of injury, function and rehabilitation, the official scientific journal of the American Academy of Physical Medicine and Rehabilitation (AAPM&R), has been accepted for coverage by MEDLINE, just six months after its launch in January 2009.
Endocrinology

Brazil Proves Developing Countries Can Use Generic Medicines To Fight HIV/AIDS Epidemic

Brazil"s nearly two-decade effort to treat people living with HIV and AIDS shows that developing countries can successfully combat the epidemic. Inexpensive generic medicines are a large part of the solution, say researchers from Brown University and the Harvard School of Public Health. Brazil did this, researchers said, largely by pursuing controversial policies that prompted pharmaceutical companies with exclusive drugs to lower their prices dramatically and generic companies to develop lower-cost alternatives for use in emerging markets. "Brazil has proved it is possible to treat people with AIDS in developing countries," said lead author Amy Nunn, assistant professor of medicine (research) at The Warren Alpert Medical School of Brown University. She added that the country saved more than $1 billion as a result of bargaining with multinational pharmaceutical companies, resulting in significant changes in global AIDS policy. That effort, Nunn said, has had a wide impact. "Before Brazil"s efforts, as recently as the year 2000," she said, "most people living with HIV/AIDS in developing countries died without receiving treatment." Details of their findings will be published in the July/August issue of Health Affairs. Francisco Bastos, a well-known AIDS epidemiologist at the Oswaldo Cruz Foundation in Rio de Janiero, and Elize da Fonseca at the University of Edinburgh in Scotland also participated in the research. Senior author Sofia Gruskin is an associate professor of health and human rights at the Harvard School of Public Health in Boston, where the initial research began. One of the biggest advances in Brazil"s push to address the advance of HIV and AIDS came in the 1990s, when the country passed a law guaranteeing free, universal access to drugs for AIDS treatment. The country also began producing generic AIDS medicines in public factories. Brazilian authorities also pressured drug companies to reduce their prices drastically for patented medicines by threatening to produce generic versions of those drugs. Brazil was working to contain the virus years before taking that step. Researchers noted that Brazil began its HIV education and prevention campaigns early in the 1980s, focusing on condom distribution and HIV testing. Health officials also targeted prevention campaigns to those vulnerable to contracting HIV, including sex workers, injecting drug users and men who have sex with men. The results were enormously beneficial. Researchers said the countryÂðs treatment initiatives also helped minimize the spread of the virus in Brazil. In doing so, health officials proved AIDS treatment was possible in a developing country. The example helped prompt sweeping changes in global public health policy and foreign aid relating to global health, with BrazilÂðs actions as an example of how to make HIV/AIDS policies more effective. Gruskin said that Brazil also spearheaded important changes in global health, trade policies, and international human rights protections related to medicines, and the country forced greater transparency about global drug prices. An example of the change: Since 2003, the United States and other developed countries once opposed to BrazilÂðs policies have invested billions of dollars annually to provide generic AIDS medicines to people in developing countries. At home, Brazil kept its HIV/AIDS epidemic confined to .5 percent of the population. Today, about 660,000 Brazilians live with the disease. Nunn said the study"s findings show that developing countries around the world can dramatically reduce AIDS-related deaths by treating patients. She added that the research highlights the value of strategic global political engagement by developing countries. Still, there are challenges ahead. The study shows that the cost of treating HIV/AIDS patients in Brazil has risen in recent years. The long-term costs of treating people living with HIV/AIDS will continue to rise in other countries as more people receive treatment, life expectancy is extended, and patients require more costly and often patented medicines. A number of organizations funded the research: The U.S. Departments of State and Education, the National Institute on Drug Abuse and the National Institute of Allergy and infectious Diseases. Mark Hollmer Brown University


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009